TY  - JOUR
AU  - Galinovic, Ivana
AU  - Fiebach, Jochen B
AU  - Boutitie, Florent
AU  - Cheng, Bastian
AU  - Cho, Tae-Hee
AU  - Ebinger, Martin
AU  - Endres, Matthias
AU  - Enzinger, Christian
AU  - Fiehler, Jens
AU  - Ford, Ian
AU  - Gregori, Johannes
AU  - Günther, Matthias
AU  - Lemmens, Robin
AU  - Muir, Keith W
AU  - Nighoghossian, N.
AU  - Roy, Pascal
AU  - Simonsen, Claus Z
AU  - Thijs, Vincent N
AU  - Wouters, Anke
AU  - Gerloff, Christian
AU  - Thomalla, Götz
AU  - Pedraza, Salvador
TI  - Effect of IV Thrombolysis With Alteplase in Patients With Vessel Occlusion in the WAKE-UP Trial.
JO  - Neurology
VL  - 104
IS  - 2
SN  - 0028-3878
CY  - [Erscheinungsort nicht ermittelbar]
PB  - Ovid
M1  - DZNE-2025-00025
SP  - e209871
PY  - 2025
AB  - Data from randomized trials on the treatment effect of pure thrombolysis in patients with vessel occlusion are lacking. We examined data from a corresponding subsample of patients from the multicenter, randomized, placebo-controlled WAKE-UP trial to determine whether MRI-guided IV thrombolysis with alteplase in unknown-onset ischemic stroke benefits patients presenting with vessel occlusion.Patients with an acute ischemic lesion visible on MRI diffusion-weighted imaging but no marked parenchymal hyperintensity on fluid-attenuated inversion recovery images were randomized to treatment with IV alteplase or placebo. The primary end point was a favorable outcome defined by a modified Rankin Scale score of 0-1 at 90 days after stroke. We investigated the interaction between vessel status and treatment effect using an unconditional logistic regression model. Treatment effects (adjusted odds ratio [aOR]) and their 95
KW  - Humans
KW  - Tissue Plasminogen Activator: administration & dosage
KW  - Tissue Plasminogen Activator: therapeutic use
KW  - Female
KW  - Male
KW  - Middle Aged
KW  - Fibrinolytic Agents: administration & dosage
KW  - Fibrinolytic Agents: therapeutic use
KW  - Aged
KW  - Ischemic Stroke: drug therapy
KW  - Ischemic Stroke: diagnostic imaging
KW  - Thrombolytic Therapy: methods
KW  - Treatment Outcome
KW  - Diffusion Magnetic Resonance Imaging
KW  - Double-Blind Method
KW  - Tissue Plasminogen Activator (NLM Chemicals)
KW  - Fibrinolytic Agents (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:39705631
C2  - pmc:PMC11666272
DO  - DOI:10.1212/WNL.0000000000209871
UR  - https://pub.dzne.de/record/274044
ER  -